Mridul Mukherji, D.Phil.

Associate Professor

UMKC School of Pharmacy
2464 Charlotte St.
HSB 4244
Kansas City, MO 64108

 

Phone: 816-235-6197
Email: mukherjim@umkc.edu

Mridul-Mukherji

Biography:

EDUCATION:

D.Phil. Degree from the University of Oxford, Oxford, UK
Year: 1998-2002
Chemical Biology

Post-Doctoral Fellowship from the Scripps Research Institute, La Jolla, CA
Year: 2002-2007
Chemical Biology

Vising Scientist at Novartis Institute of Functional Genomics, La Jolla, CA
Year: 2002-2007

RESEARCH INTERESTS:

Dr Mukherji’s research interests revolve around hypoxia-inducible-factor (HIF)-pathway and its regulation by iron(II), 2OG-dependent dioxygenases. His long term goal is to use his experience in the HIF pathway and dioxygenases/ demethylases to delineate their roles in normal development/ disease states, and identify small molecule modulators that can be used to develop more effective strategies for therapeutic intervention. For critical contributions on HIF pathway one of Dr Mukherji’s mentors, Sir Peter J. Ratcliffe, received the 2016 Lasker Award (aka America’s Nobel) in Basic Medical Research. Dr Mukherji significantly contributed in 2 of the 5 key publications cited by the Lasker foundation.

Dr Mukherji received several grants including one from US Department of Defence for close to half million dollars. He serves as an editorial board member of several international scientific journals and has also received a number of teaching awards including:

2012 Teacher of the Year Runner-up award by doctor of pharmacy class of 2015
2015 Teacher of the Year Runner-up award by doctor of pharmacy class of 2018
2016 Teacher of the Year award by doctor of pharmacy class of 2019
2018 Teacher of the Year Runner-up award by doctor of pharmacy class of 2021

SELECTED PUBLICATIONS:

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim Av, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation. Science, 2001, 292, 468-472. Comments: Zhu H, Bunn HF: How do cells sense oxygen? Science, 2001, 292, 449-51.
Note: This publication was cited as one of the five key publications for a Lasker award (aka America’s Nobel) to Sir Peter J. Ratcliffe in 2016.

Mukherji M, Chien W, Kershaw NJ, Clifton IJ, Schofield CJ, Wierzbicki AS, Lloyd MD: Structure–function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum’s disease. Human Molecular Genetics, 2001, 10, 1971-1982.

Apstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 2001, 107, 43-54. Comments: Semenza GL: HIF-1, O2, and the 3 PHDs: How Animal Cells Signal Hypoxia to the Nucleus. Cell, 2001, 107, 1-3.
Note: This publication was cited as one of the five key publications for a Lasker award (aka America’s Nobel) to Sir Peter J. Ratcliffe in 2016.

Mukherji M, Kershaw NJ, Schofield CJ, Wierzbicki AS, Lloyd MD: Utilization of sterol carrier protein-2 by phytanoyl-CoA 2-hydroxylase in the peroxisomal alpha oxidation of phytanic acid. Chemistry and Biology (aka Cell Chemical Biology), 2002, 9, 597-605.

Mukherji M, Bell R, Supekova L, Wang Y, Orth AP, Batalov S, Miraglia L, Huesken D, Lange J, Martin C, Sahasrabudhe S, Reinhardt M, Natt F, Hall J, Mickanin C, Labow M, Chanda SK, Cho CY, Schultz PG: Genome-wide Functional Analysis of Human Cell Cycle Regulators. Proceedings of the National Academy of Sciences, USA, 2006, 103, 14819-14824.

Mukherji M, Brill LM, Ficarro SB, Hampton GM, Schultz PG: A Phosphoproteomic Analysis of the ErbB2 Receptor Tyrosine Kinase Signaling Pathways. Biochemistry, 2006, 45, 15529-15540. Featured article: Chosen as a hot article by ACS Editors.

Ponnaluri VK, Vavilala DT, Putty S, Gutheil WG, Mukherji M: Identification of non-histone substrates for JMJD2A-C histone demethylases. Biochemical Biophysical Research Communications, 2009, 390, 280-284.

Ponnaluri VK, Maciejewski JP, Mukherji M: A Mechanistic Overview of TET-mediated 5-Methylcytosine Oxidation. Biochemical Biophysical Research Communications, 2013, 436, 115-120.

Vavilala DT, O’Bryhim BE, Ponnaluri VK, White RS, Radel J, Symons RCA, Mukherji M: Honokiol Inhibits Pathological Retinal Neovascularization in Oxygen-Induced Retinopathy Mouse Model. Biochemical Biophysical Research Communications, 2013, 438, 697-702.

Vavilala DT, Ponnaluri VK, Kanjilal D, Mukherji M: Evaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases. PLoS ONE, 2014, 9, e113717.

Subhani S, Vavilala DT, Mukherji M: HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. Angiogenesis, 2016, 19, 257-73.

Jaiswal M, Bhar S, Vemula H, Prakash S, Ponnaluri VK, Gutheil WG, Mukherji M: Convenient expression, purification and quantitative liquid chromatography-tandem mass spectrometry-based analysis of TET2 5-methylcytosine demethylase. Protein Expression and Purification, 2017, 132, 143-151.